Cabaletta Bio (CABA) has released an update to notify the public and investors about a regulation fd disclosure.
Cabaletta Bio, Inc. announced on February 1, 2024, that the FDA has awarded Orphan Drug Designation to their investigational therapy CABA-201, a CAR T cell therapy targeting CD19, for the treatment of idiopathic inflammatory myopathies. This designation is intended to advance the development of treatments for rare diseases.
For further insights into CABA stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
